Amgen (AMGN) is expected to report a slight Q2 beat as key product script trends remain solid, UBS said in an earnings preview on Monday. The Q2 results are due Aug. 5.
UBS analysts pointed to key growth drivers such as Repatha and Evenity. They also said Prolia and Xgeva remained solid in Q2.
"We have not yet seen aggressive pricing from biosimilar players that have entered the US market," the analysts said.
They said a guidance upgrade would be a bullish signal amid the uncertainty from Prolia & Xgeva biosimilar impact into H2.
UBS kept its neutral rating on the stock while raising its price target to $326 from $315.
Price: 295.02, Change: +0.26, Percent Change: +0.09
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。